Pal-AHK vs SLU-PP-332
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Pal-AHKRecovery & RepairFat Loss & Metabolic
SLU-PP-332- Summary
- Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Half-Life
- Extended (lipid depot effect in stratum corneum)
- Not established in humans; rodent pharmacokinetics suggest hours
- Admin Route
- Topical
- Oral (research), Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 0.01–0.05% in formulation
- Not established for humans; rodent studies used ~100 mg/kg/day
- Frequency
- Once or twice daily
- Once daily in rodent studies
- Key Benefits
- Enhanced skin penetration vs. unmodified AHK-Cu
- Stimulates dermal collagen and elastin production
- Promotes hair follicle anagen phase
- Antioxidant and wound healing activity
- Firming and plumping effect on aging skin
- Improved bioavailability via lipid bilayer incorporation
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Side Effects
- Generally well-tolerated
- Mild irritation at high concentrations in sensitive skin
- Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Stacks With
- —
- —